Syndax Pharmaceutica
SNDX
Delayed Nasdaq - 11/17 10:00:02 pm
8.81USD
+3.16%
Prev.8.5400
Open8.5100
High9.1500
Low8.5100
Volume356 543
Last news
Financials
Sales 2017 1,21 M
EBIT 2017 -62,0 M
R. net 2017 -63,0 M
Tréso. 2017 135 M
Rend. 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 65,8x
EV / Sales 2018 58,9x
Capitalization 215 M
Company
Syndax Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of cancer therapies.It focuses on the development and commercialization of its lead product candidate, entinostat, an epigenetic therapy for treatment-resistant cancers.The company...
Sector :
Biopharmaceuticals
Calendar :
2018-03-01 Earnings Release
Trading Rating :
Investor Rating :
Technical analysis trends
Short TermMid-TermLong Term
TrendBearishBearishNeutral
Resistance10,511,714,7
Spread/Res.-16%-25%-40%
Spread/Supp.5,3%5,3%32%
Support8,378,376,68